Spots Global Cancer Trial Database for Glivec Phase II Pediatric Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Glivec Phase II Pediatric Study
Official Title: Open Label, Pilot Phase II Study of Glivec in Children and Adolescents With Life Threatening Diseases Known to Be Associated With One or More Glivec-Sensitive Tyrosine Kinases
Study ID: NCT00180830
Conditions
Study Description
Brief Summary: The purpose of this study is to determine whether Glivec is effective, in children, adolescents and young adults, in the treatment of malignant disease in which evidence suggests a potential pathogenic role of one or more of the tyrosine kinases known to be inhibited by Glivec.
Detailed Description:
Keywords
Eligibility
Minimum Age: 6 Months
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Institut Gustave-Roussy, Villejuif, , France
Emma Kinderziekenhuis AMC, Amsterdam, , Netherlands
Birmingham Children's Hospital, Birmingham, , United Kingdom
Contact Details
Name: Gilles Vassal, MD,PhD
Affiliation: Gustave Roussy, Cancer Campus, Grand Paris
Role: STUDY_CHAIR
Name: Bruce Morland
Affiliation: Birmingham Children's Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
